| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroblastoma | 26 | 2026 | 547 | 6.000 |
Why?
|
| Methotrexate | 5 | 2025 | 348 | 2.150 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2025 | 194 | 1.800 |
Why?
|
| Antineoplastic Agents | 9 | 2026 | 1814 | 1.660 |
Why?
|
| Neoplasms | 10 | 2026 | 2985 | 1.630 |
Why?
|
| Cyclopentanes | 2 | 2024 | 21 | 1.530 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2026 | 1324 | 1.350 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2026 | 1265 | 1.280 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2020 | 881 | 1.220 |
Why?
|
| Pyrimidines | 2 | 2024 | 448 | 1.200 |
Why?
|
| Child | 49 | 2026 | 26243 | 1.110 |
Why?
|
| Transplantation Conditioning | 2 | 2020 | 327 | 1.050 |
Why?
|
| Pediatrics | 6 | 2026 | 1248 | 1.050 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 263 | 1.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2025 | 1276 | 1.000 |
Why?
|
| Hepatoblastoma | 3 | 2024 | 204 | 0.970 |
Why?
|
| Drugs, Generic | 2 | 2026 | 16 | 0.970 |
Why?
|
| Biosimilar Pharmaceuticals | 2 | 2026 | 9 | 0.960 |
Why?
|
| Child, Preschool | 28 | 2026 | 15036 | 0.910 |
Why?
|
| Adolescent | 31 | 2026 | 20875 | 0.910 |
Why?
|
| Bone Neoplasms | 2 | 2019 | 471 | 0.840 |
Why?
|
| Induction Chemotherapy | 3 | 2022 | 55 | 0.820 |
Why?
|
| Antibodies, Monoclonal | 4 | 2026 | 978 | 0.790 |
Why?
|
| Algorithms | 3 | 2025 | 1669 | 0.690 |
Why?
|
| Legislation, Drug | 1 | 2020 | 8 | 0.670 |
Why?
|
| Liver Neoplasms | 4 | 2024 | 1366 | 0.660 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 27 | 0.660 |
Why?
|
| Humans | 62 | 2026 | 130459 | 0.650 |
Why?
|
| Survival Rate | 7 | 2026 | 2110 | 0.650 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2020 | 35 | 0.640 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2020 | 27 | 0.640 |
Why?
|
| Off-Label Use | 2 | 2025 | 29 | 0.630 |
Why?
|
| Neuroendocrine Tumors | 1 | 2021 | 70 | 0.620 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 79 | 0.620 |
Why?
|
| Sodium Bicarbonate | 1 | 2020 | 55 | 0.620 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2020 | 91 | 0.620 |
Why?
|
| Infant | 20 | 2026 | 13308 | 0.610 |
Why?
|
| Prognosis | 10 | 2026 | 4865 | 0.590 |
Why?
|
| Orchiectomy | 1 | 2019 | 46 | 0.590 |
Why?
|
| Follow-Up Studies | 11 | 2026 | 5185 | 0.580 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2019 | 17 | 0.580 |
Why?
|
| Phenylurea Compounds | 1 | 2019 | 57 | 0.570 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2018 | 6 | 0.570 |
Why?
|
| Neutropenia | 1 | 2020 | 209 | 0.570 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2022 | 617 | 0.570 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2021 | 124 | 0.570 |
Why?
|
| Periosteum | 1 | 2019 | 32 | 0.570 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2019 | 137 | 0.560 |
Why?
|
| Radiotherapy | 1 | 2019 | 119 | 0.560 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 559 | 0.560 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2019 | 92 | 0.550 |
Why?
|
| Alemtuzumab | 1 | 2018 | 89 | 0.550 |
Why?
|
| Quinazolines | 1 | 2019 | 176 | 0.540 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 112 | 0.540 |
Why?
|
| Organophosphonates | 1 | 2018 | 21 | 0.540 |
Why?
|
| Twins, Monozygotic | 1 | 2018 | 124 | 0.540 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2018 | 81 | 0.540 |
Why?
|
| Cytosine | 1 | 2018 | 56 | 0.530 |
Why?
|
| Doxorubicin | 1 | 2019 | 289 | 0.530 |
Why?
|
| Hearing Loss | 3 | 2025 | 203 | 0.530 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2018 | 148 | 0.530 |
Why?
|
| BK Virus | 1 | 2018 | 58 | 0.520 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 142 | 0.520 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2018 | 166 | 0.520 |
Why?
|
| Cystitis | 1 | 2018 | 47 | 0.520 |
Why?
|
| Polyomavirus Infections | 1 | 2018 | 87 | 0.510 |
Why?
|
| Tumor Virus Infections | 1 | 2018 | 131 | 0.510 |
Why?
|
| Bacterial Infections | 1 | 2020 | 327 | 0.510 |
Why?
|
| Combined Modality Therapy | 2 | 2026 | 1212 | 0.510 |
Why?
|
| Infection Control | 1 | 2018 | 158 | 0.510 |
Why?
|
| Retrospective Studies | 19 | 2026 | 17619 | 0.500 |
Why?
|
| Female | 32 | 2026 | 70516 | 0.500 |
Why?
|
| Osteosarcoma | 1 | 2019 | 275 | 0.490 |
Why?
|
| Male | 29 | 2026 | 64573 | 0.490 |
Why?
|
| Gene Rearrangement | 1 | 2018 | 322 | 0.490 |
Why?
|
| United States Food and Drug Administration | 4 | 2026 | 158 | 0.480 |
Why?
|
| Apoptosis | 2 | 2021 | 1826 | 0.470 |
Why?
|
| Surgical Oncology | 1 | 2025 | 15 | 0.450 |
Why?
|
| Thoracic Wall | 1 | 2015 | 40 | 0.450 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 315 | 0.440 |
Why?
|
| Cisplatin | 3 | 2025 | 274 | 0.430 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 1547 | 0.420 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 213 | 0.410 |
Why?
|
| Disease Management | 1 | 2017 | 556 | 0.390 |
Why?
|
| Sarcoma | 1 | 2015 | 218 | 0.380 |
Why?
|
| NEDD8 Protein | 2 | 2024 | 20 | 0.380 |
Why?
|
| Young Adult | 10 | 2025 | 10034 | 0.380 |
Why?
|
| Heart Defects, Congenital | 1 | 2024 | 1879 | 0.370 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2025 | 1605 | 0.360 |
Why?
|
| Antiviral Agents | 1 | 2018 | 805 | 0.360 |
Why?
|
| Cell Proliferation | 1 | 2019 | 2462 | 0.350 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2022 | 67 | 0.340 |
Why?
|
| Surgeons | 1 | 2025 | 289 | 0.320 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1284 | 0.320 |
Why?
|
| Drug Therapy | 1 | 2020 | 85 | 0.300 |
Why?
|
| Treatment Outcome | 6 | 2025 | 12838 | 0.290 |
Why?
|
| Proton Therapy | 2 | 2022 | 155 | 0.290 |
Why?
|
| Emergencies | 1 | 2020 | 171 | 0.280 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 913 | 0.280 |
Why?
|
| Drug Monitoring | 2 | 2025 | 291 | 0.280 |
Why?
|
| Clinical Competence | 1 | 2025 | 1045 | 0.270 |
Why?
|
| United States | 7 | 2026 | 11994 | 0.270 |
Why?
|
| Neoplasm, Residual | 3 | 2022 | 133 | 0.260 |
Why?
|
| Maximum Tolerated Dose | 2 | 2025 | 174 | 0.260 |
Why?
|
| Transplantation, Autologous | 3 | 2025 | 254 | 0.250 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2021 | 1005 | 0.250 |
Why?
|
| Therapeutic Equivalency | 2 | 2026 | 15 | 0.240 |
Why?
|
| Drug Substitution | 2 | 2026 | 27 | 0.240 |
Why?
|
| Drug Approval | 2 | 2026 | 48 | 0.240 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 902 | 0.230 |
Why?
|
| Thiosulfates | 1 | 2025 | 7 | 0.220 |
Why?
|
| Biopsy | 2 | 2018 | 1240 | 0.210 |
Why?
|
| Aftercare | 1 | 2026 | 157 | 0.210 |
Why?
|
| Cell Line, Tumor | 3 | 2022 | 3712 | 0.210 |
Why?
|
| Stem Cell Transplantation | 1 | 2025 | 225 | 0.210 |
Why?
|
| Dexamethasone | 1 | 2025 | 250 | 0.200 |
Why?
|
| Medical Oncology | 2 | 2022 | 243 | 0.190 |
Why?
|
| N-Myc Proto-Oncogene Protein | 2 | 2022 | 57 | 0.190 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2026 | 813 | 0.190 |
Why?
|
| Caregivers | 2 | 2026 | 596 | 0.180 |
Why?
|
| Prospective Studies | 4 | 2022 | 6421 | 0.180 |
Why?
|
| Tracheostomy | 1 | 2024 | 211 | 0.180 |
Why?
|
| Cancer Survivors | 1 | 2026 | 281 | 0.180 |
Why?
|
| Polypharmacy | 1 | 2021 | 36 | 0.170 |
Why?
|
| Thoracic Neoplasms | 1 | 2021 | 36 | 0.170 |
Why?
|
| Ganglioneuroblastoma | 1 | 2021 | 7 | 0.170 |
Why?
|
| Ganglioneuroma | 1 | 2021 | 15 | 0.170 |
Why?
|
| Incidence | 3 | 2024 | 3338 | 0.170 |
Why?
|
| MyoD Protein | 1 | 2021 | 22 | 0.170 |
Why?
|
| Radioisotopes | 1 | 2021 | 26 | 0.170 |
Why?
|
| Drug Interactions | 1 | 2022 | 236 | 0.170 |
Why?
|
| Radionuclide Imaging | 1 | 2021 | 113 | 0.170 |
Why?
|
| Receptors, Peptide | 1 | 2021 | 60 | 0.170 |
Why?
|
| Infusions, Intravenous | 2 | 2025 | 531 | 0.160 |
Why?
|
| Government Regulation | 1 | 2020 | 44 | 0.160 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 155 | 0.160 |
Why?
|
| Animals | 6 | 2022 | 33709 | 0.160 |
Why?
|
| Risk Factors | 3 | 2019 | 11007 | 0.150 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 101 | 0.150 |
Why?
|
| Fatty Acids | 1 | 2022 | 373 | 0.150 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 172 | 0.150 |
Why?
|
| Medication Errors | 1 | 2021 | 192 | 0.150 |
Why?
|
| Quality Improvement | 1 | 2026 | 715 | 0.150 |
Why?
|
| Drug Administration Schedule | 2 | 2021 | 723 | 0.150 |
Why?
|
| Immunotherapy | 2 | 2026 | 759 | 0.150 |
Why?
|
| Vincristine | 1 | 2020 | 188 | 0.150 |
Why?
|
| Etoposide | 1 | 2019 | 111 | 0.150 |
Why?
|
| Positron-Emission Tomography | 1 | 2021 | 283 | 0.150 |
Why?
|
| Vocal Cord Paralysis | 1 | 2020 | 68 | 0.150 |
Why?
|
| Sodium | 1 | 2020 | 280 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2021 | 182 | 0.150 |
Why?
|
| Immunologic Factors | 1 | 2020 | 190 | 0.140 |
Why?
|
| Adult | 8 | 2026 | 31103 | 0.140 |
Why?
|
| Drug Synergism | 1 | 2019 | 236 | 0.140 |
Why?
|
| Cell Cycle | 1 | 2021 | 593 | 0.140 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 356 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2019 | 237 | 0.140 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 209 | 0.140 |
Why?
|
| Administration, Intravesical | 1 | 2018 | 29 | 0.140 |
Why?
|
| Drug Hypersensitivity | 1 | 2019 | 99 | 0.140 |
Why?
|
| Tissue Distribution | 1 | 2018 | 362 | 0.140 |
Why?
|
| Gangliosides | 1 | 2018 | 72 | 0.140 |
Why?
|
| Wilms Tumor | 1 | 2019 | 117 | 0.140 |
Why?
|
| Rhabdomyosarcoma | 1 | 2021 | 230 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 383 | 0.140 |
Why?
|
| Desensitization, Immunologic | 1 | 2019 | 116 | 0.130 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 272 | 0.130 |
Why?
|
| Mice, Nude | 1 | 2019 | 699 | 0.130 |
Why?
|
| Blood Transfusion | 1 | 2019 | 292 | 0.130 |
Why?
|
| Allografts | 1 | 2018 | 220 | 0.130 |
Why?
|
| Lower Extremity | 1 | 2019 | 184 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 719 | 0.130 |
Why?
|
| Mucositis | 1 | 2017 | 20 | 0.120 |
Why?
|
| Risk | 1 | 2018 | 724 | 0.120 |
Why?
|
| Bone Marrow | 1 | 2018 | 317 | 0.120 |
Why?
|
| Hodgkin Disease | 1 | 2019 | 307 | 0.120 |
Why?
|
| Anticoagulants | 1 | 2021 | 601 | 0.120 |
Why?
|
| Thrombosis | 1 | 2021 | 498 | 0.120 |
Why?
|
| Area Under Curve | 1 | 2017 | 303 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2020 | 1440 | 0.120 |
Why?
|
| Fluid Therapy | 1 | 2017 | 141 | 0.120 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 573 | 0.120 |
Why?
|
| Topotecan | 2 | 2026 | 49 | 0.110 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 782 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2024 | 975 | 0.110 |
Why?
|
| Acute Disease | 1 | 2018 | 1153 | 0.110 |
Why?
|
| Infant, Newborn | 4 | 2024 | 8623 | 0.110 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 2330 | 0.100 |
Why?
|
| Delphi Technique | 1 | 2025 | 281 | 0.100 |
Why?
|
| Cyclophosphamide | 2 | 2026 | 426 | 0.100 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 691 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 394 | 0.090 |
Why?
|
| Cytokines | 1 | 2018 | 1332 | 0.090 |
Why?
|
| Age Factors | 1 | 2018 | 2822 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2025 | 792 | 0.080 |
Why?
|
| Signal Transduction | 2 | 2020 | 4662 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 702 | 0.070 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 668 | 0.070 |
Why?
|
| Mice | 2 | 2021 | 18185 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2012 | 561 | 0.060 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 353 | 0.060 |
Why?
|
| Injection, Intratympanic | 1 | 2025 | 2 | 0.060 |
Why?
|
| Costa Rica | 1 | 2025 | 14 | 0.060 |
Why?
|
| Gels | 1 | 2025 | 59 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2005 | 242 | 0.050 |
Why?
|
| Aspirin | 1 | 2005 | 212 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2005 | 588 | 0.050 |
Why?
|
| Piperidines | 1 | 2025 | 221 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2005 | 267 | 0.050 |
Why?
|
| Indazoles | 1 | 2022 | 35 | 0.050 |
Why?
|
| Protons | 1 | 2022 | 94 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2012 | 1219 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2025 | 350 | 0.040 |
Why?
|
| Dosage Forms | 1 | 2021 | 9 | 0.040 |
Why?
|
| Benzamides | 1 | 2022 | 125 | 0.040 |
Why?
|
| Bays | 1 | 2021 | 7 | 0.040 |
Why?
|
| Drug Storage | 1 | 2021 | 18 | 0.040 |
Why?
|
| Medication Reconciliation | 1 | 2021 | 17 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2022 | 145 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2025 | 821 | 0.040 |
Why?
|
| Pamphlets | 1 | 2021 | 21 | 0.040 |
Why?
|
| Maternal Age | 1 | 2022 | 136 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1218 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2022 | 219 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2024 | 498 | 0.040 |
Why?
|
| Thoracoscopy | 1 | 2021 | 41 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2022 | 156 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2005 | 626 | 0.040 |
Why?
|
| Communication Barriers | 1 | 2021 | 46 | 0.040 |
Why?
|
| Nonprescription Drugs | 1 | 2021 | 57 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2021 | 71 | 0.040 |
Why?
|
| SEER Program | 1 | 2022 | 213 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2024 | 3119 | 0.040 |
Why?
|
| Health Literacy | 1 | 2021 | 77 | 0.040 |
Why?
|
| Operative Time | 1 | 2021 | 199 | 0.040 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 93 | 0.040 |
Why?
|
| Hoarseness | 1 | 2020 | 13 | 0.040 |
Why?
|
| Quinolines | 1 | 2021 | 117 | 0.040 |
Why?
|
| Imidazoles | 1 | 2021 | 219 | 0.040 |
Why?
|
| Language | 1 | 2021 | 219 | 0.040 |
Why?
|
| Respiratory Sounds | 1 | 2020 | 78 | 0.040 |
Why?
|
| Relative Biological Effectiveness | 1 | 2019 | 9 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 597 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 1404 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2019 | 230 | 0.030 |
Why?
|
| Registries | 1 | 2024 | 1615 | 0.030 |
Why?
|
| Allergens | 1 | 2019 | 344 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2005 | 2828 | 0.030 |
Why?
|
| Kidney | 1 | 2022 | 1280 | 0.030 |
Why?
|
| Parents | 1 | 2021 | 1123 | 0.030 |
Why?
|
| Texas | 1 | 2022 | 3663 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 1619 | 0.020 |
Why?
|
| Hawaii | 1 | 2012 | 6 | 0.020 |
Why?
|
| Publications | 1 | 2012 | 36 | 0.020 |
Why?
|
| Faculty | 1 | 2012 | 99 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 222 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 5048 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7463 | 0.020 |
Why?
|
| Mutation | 1 | 2021 | 6062 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 20876 | 0.010 |
Why?
|
| Receptors, Purinergic P2Y1 | 1 | 2005 | 8 | 0.010 |
Why?
|
| Mathematical Computing | 1 | 2005 | 9 | 0.010 |
Why?
|
| Receptors, Purinergic P2 | 1 | 2005 | 16 | 0.010 |
Why?
|
| Premedication | 1 | 2005 | 39 | 0.010 |
Why?
|
| Platelet Aggregation | 1 | 2005 | 100 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2005 | 316 | 0.010 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2005 | 161 | 0.010 |
Why?
|
| Middle Aged | 1 | 2024 | 28393 | 0.010 |
Why?
|
| Homozygote | 1 | 2005 | 533 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 777 | 0.010 |
Why?
|
| Exons | 1 | 2005 | 759 | 0.010 |
Why?
|
| Blood Platelets | 1 | 2005 | 313 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 1674 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 2590 | 0.010 |
Why?
|